Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. 

Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Health Care

Nuclear

Orano Med

Orano Med's headquarters in Plano, TX, United States

Pascal Mirocha

Nicolas Bozovic

Julien Torgue

Thomas Priem

Alison Tise

Mamoudou Thiaw

J. Robert Chastain (Rob)

Philippe Brisset

Amy Wong Ph.D., Chemistry

Haley Lozano-Sprague

Sadaf Qureshi

Guillaume Porche

Carter Rose

Tania Stallons

Aaron Schatzmann

Francesco Santo

Maria Russo

Description

People (13)

J. Robert Chastain (Rob)

Jessica B Johnson

Amy Wong Ph.D., Chemistry

Aaron Schatzmann

Varaidzo M.

Amanda Reyes

Quy Nguyen

Sharon Gorgolini

Jacklyn Montoya

Scott Khanthaphone

Latrice Ford

Zoey Smith

Tania Stallons

Jobs